Fresh analysis indicates that people who discontinue popular GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who end conventional diet and exercise regimens.
Published data in a leading medical journal shows that while overweight individuals can lose a large proportion of their body weight while on the medication, the mass comes back at an estimated rate of nearly a kilo each month upon discontinuation.
"People purchasing these medications need to be aware of the risk of fast weight regain when the treatment is stopped," warns lead investigator Dr. Susan Jebb.
Such speed of regain implies a return to pre-treatment weight within about a year and a half.
Weighing Treatments
The analysis, which reviewed dozens of studies involving thousands of participants, contrasted the results of GLP-1 agonists with other pills.
The team emphasize that people who shed pounds through lifestyle changes alone generally experience a more gradual creep back—approximately 100 grams monthly—post-intervention.
Understanding the Quick Regain
Doctors propose the mode of action of the jabs is key to understanding the accelerated regain.
These medications imitate a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Sustained high doses of GLP-1 levels far above than the body's typical production may cause the body to produce less of its own natural hormone, and could reduce sensitivity to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this medication leads to appetite is no longer kept in check, making overeating far more likely."
An Ongoing Disease?
Medical guidelines suggest the jabs for individuals with weight-linked medical conditions, alongside recommended diet and exercise modifications.
Many experts argue that, considering the significant potential of relapse, the treatment should be considered long-term.
This opinion is echoed by pharmaceutical companies, who note that the results "underscore the chronic nature of obesity," akin to managing conditions like hypertension.
User Testimonies
Users who have stopped the jabs report a intense return of appetite.
"It was like a switch flipping and you become extremely hungry," said one woman.
This difficulty is compounded if patients have not adopted sustainable dietary or behavioural modifications during therapy.
Growing Adoption
Figures suggest that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial.
- Adoption is higher among females compared to males.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion obtain the drugs through private healthcare rather than public health services.
Finally, researchers caution that while these medications are effective agents for weight loss, they are not a magic cure and maintained weight loss relies on ongoing behavioural changes.
